Miami, FL – July 10, 2020 ( NewsWire) —, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, reports on Generex Biotechnology Corporation (OTCQB: GNBT).

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. 

Average daily volume for GNBT is 300 thousand shares. See how the volume does in the morning hours of trading.

Generex Biotechnology Corporation Press Release:

MIRAMAR, Fla., July 10, 2020 (GLOBE NEWSWIRE) — Generex Biotechnology Corporation ( (OTCQB:GNBT) today announced call-in details for today’s investor conference call on Friday July 10(th) 2020 at 4:15 PM Eastern time.

The access information for the investor conference call is as follows:

Domestic US/Canada — 1-(877) 830–2586

Direct Toll / International – 1-(785) 424-1734

Program Title: NuGenerex Immuno–Oncology — Investor Conference Call

Conference ID — 66974


— SEC filings and corporate update for NuGenerex Immuno-Oncology as a separate public company — NuGenerex Immuno-Oncology Listing Plans — Status of COVID-19 Vaccine initiatives — Published study results from AE37 Phase II breast cancer trial with 10-year follow-up — Update on the Phase II trial of AE37 with Pembrolizumab (Keytruda(R)) for the Treatment of Triple Negative Breast Cancer — New opportunity to revitalize development of Ii-Key-Hemagglutinin peptide vaccine originally developed for avian influenza and 2009 swine flu for emerging swine flu virus

On the call, Generex President & Chief Executive Officer, Joseph Moscato and his team will provide an overview of how NuGenerex Immuno-Oncology’s Ii-Key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus and a review of work with development partners & government agencies to implement Ii-Key peptide vaccine technology to implement a rapid response vaccination strategy for the SARS-CoV-2 and emerging swine influenza (Swine Flu) viruses.

Mr. Moscato said, “I look forward to speaking with our shareholders to discuss the listing of NuGenerex Immuno-Oncology on a national exchange and our plans to expand the Ii-Key technology platform to generate new immunotherapies and vaccines. We have a number of exciting initiatives that I am eager to present, and as always, we welcome questions from shareholders during the call.”

About NuGenerex Immuno-Oncology

NuGenerex Immuno-Oncology, a subsidiary of Generex Biotechnology, is a clinical stage oncology company developing immunotherapeutic peptide vaccines based on the CD4 T-Cell activation platform, Ii-Key. NuGenerex Immuno-Oncology (NGIO) has been spun out of Generex as a separate, independent public company to advance the platform Ii-Key technology, particularly in combination with the immune checkpoint inhibitors. NGIO is currently engaged in a Phase II clinical trial of its lead cancer immunotherapeutic vaccine AE37 in combination with pembrolizumab (Merck’s Keytruda(R)) for the treatment of triple negative breast cancer.

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plan,” “believes,” “will,” “achieve,” “anticipate,” “would,” “should,” “subject to” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato


Todd Falls

1-800-391-6755 Extension 222 

About is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies.  Through its evolution, found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization.  We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth.  Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community.  Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of and should not be construed as an offer or solicitation to buy or sell securities. The information may include certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks., or its associates may have a position either long or short in any company mentioned herein. Please read our full disclosure, which can be found here, Please consult an investment professional before investing in anything viewed within this article or any other portion of In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the website.

Add a Comment to this Post